中国血液净化

中国血液净化 ›› 2026, Vol. 25 ›› Issue (03): 262-264.doi: 10.3969/j.issn.1671-4091.2026.03.018

• 短篇报道 • 上一篇    

罗沙司他致维持性血液透析患者甲状腺功能减退一例

周清华  宋 利  尹 燕  刘双信  崔冬梅  赵立艳  康小莉  黄 欣  廖俊杰  胡宇航  冯仲林   

  1. 510080 广州，1南方医科大学附属广东省人民医院(广东省医学科学院)肾内科
  • 收稿日期:2025-08-04 修回日期:2025-12-25 出版日期:2026-03-12 发布日期:2026-03-12
  • 通讯作者: 尹燕 E-mail:yinyan1019@139.com
  • 基金资助:
    广东省医学科学技术研究基金项目(A2024441)；广东省卫济医学发展基金会科研基金(K-20240105，K-20240110)

Roxadustat-induced hypothyroidism in a maintenance hemodialysis patient: report of a case

ZHOU Qing-hua, SONG Li, YIN Yan, LIU Shuang-xin, CUI Dong-mei, ZHAO Li-yan, KANG Xiao-li, HUANG Xin, LIAO Jun-jie, HU Yu-hang, FENG Zhong-lin   

  1. Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China
  • Received:2025-08-04 Revised:2025-12-25 Online:2026-03-12 Published:2026-03-12
  • Contact: 510080 广州，1南方医科大学附属广东省人民医院(广东省医学科学院)肾内科 E-mail:yinyan1019@139.com

摘要： 本篇报道一例罗沙司他治疗肾性贫血引发甲状腺功能减退症的病例。患者为93岁女性，接受维持性血液透析治疗，因“反复头晕十余年，慢性肾脏病5期、肾性贫血”就诊，规律透析一年余，因肾性贫血接受罗沙司他治疗，在开始罗沙司他口服治疗的第3天，患者表现出甲状腺功能减退的症状，并伴有实验室检查结果异常。经过内分泌科会诊和鉴别诊断，确诊为中枢性甲状腺功能减退。患者接受左甲状腺素钠治疗后甲状腺功能未能得到改善，停用罗沙司他后，甲状腺功能逐渐恢复至正常水平。鉴于此病例，建议对接受罗沙司他治疗的患者，在用药期间监测甲状腺功能，必要时考虑采用甲状腺激素替代治疗或暂停使用该药物。

关键词: 肾性贫血, 罗沙司他, 甲状腺功能

Abstract: This report presents a case of hypothyroidism induced by roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of renal anemia. The patient was a 93-year-old female undergoing maintenance hemodialysis, and was admitted due to “recurrent dizziness for more than 10 years, chronic kidney disease stage 5 (CKD stage 5), and renal anemia”. She had received regular hemodialysis for over one year and was treated with oral roxadustat for renal anemia. On the third day after roxadustat therapy, the patient developed symptoms of hypothyroidism, accompanied by abnormal laboratory test results. Following consultation with the Department of Endocrinology and comprehensive differential diagnosis, she was confirmed to have central hypothyroidism. Despite treatment with levothyroxine sodium (Euthyrox), her thyroid function failed to improve; however, it gradually returned to normal after discontinuing roxadustat. In view of this case, we recommended that thyroid function should be regularly monitored when the patients receive roxadustat therapy. When necessary, thyroid hormone replacement therapy is initiated or roxadustat is temporarily suspended. 

Key words: Renal anemia, Roxadustat, Thyroid function

中图分类号: